The individualized numbers should be useful to national disease management efforts, the researchers added. "Our country-specific results can be extrapolated to guide in-country policy for laboratory capacity and for designing effective treatment recommendations."
PETTS data collection continues, they noted. "The effect of the Green Light Committee initiative in combating acquired resistance to second-line drugs, the timing of acquired resistance, and the role of specific genetic mutations in different regions of the world are also being assessed."
The U.S. Agency for International Development, the Centers for Disease Control and Prevention, the National Institutes of Health, and the Korean Ministry of Health and Welfare sponsored the study. The authors declared no financial conflicts.